Danwang Medical Raises ￥10M in Angel Round

(VCBeat) Feb. 8, 2021 -- Recently, Danwang Medical Technology (Shanghai) Co., Ltd. ("Danwang Medical") announced the closing of angel round financing worth tens of millions, led by Co-win Ventures, with participation from Lingxian Jiankang Fund. The funds raised will be mainly used for the construction of Danwang Medical's organ standardization system, product R&D and upgrading, and the promotion of its business and commercial services.

Danwang Medical is committed to the development and application of organoids, focusing on the precise diagnosis and treatment of tumors. The company provides patients with personalized diagnosis and treatment solutions, and high-quality service platform of organoids for new drug R&D enterprises. 

Danwang Medical has the world's leading organoid technology platform and established the organoid culture system for the normal tissues and tumor tissues of human organs such as lung, pancreas, breast, stomach, intestine, and liver. Danwang Medical is a pioneer in the field of organ-like tissues.

Relying on its stable technology platform, Danwang Medical has optimized and established the standard and quality system of organoids culture that can meet the requirements of clinical diagnosis and drug screening at the same time. Danwang Medical has carried out clinical trials of organoids with a number of first-class hospitals at grade 3.

Founded in 2009, Co-win Ventures is an angel and early-stage investor in TMT and Healthcare. They keep nurturing growth-stage companies graduated from their angel investment portfolio and our funds encompass the whole financial product chain, including seed funds, VC funds and PE funds. Co-win Ventures' business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing, Shenzhen and Hong Kong.

Lingxian Jiankang Fund is a venture capital firm founded by senior healthcare investors dedicated to early-stage investments in the healthcare industry. The company deeply explores the development trend and investment opportunities of the medical and healthcare industry.